X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-31 | COGT | Cogent Biosciences, Inc. | Fairmount Funds Management LLC | Dir | S - Sale+OE | $34.66 | -7,000,000 | 5,503,418 | -56% | -$242,620,000 | |||||
2026-03-31 | ABEO | Abeona Therapeutics Inc. | Seshadri Vishwas | CEO | S - Sale | $4.38 | -29,985 | 1,430,423 | -2% | -$131,481 | ||||||
2026-03-27 | SLNO | Soleno Therapeutics Inc | Manning Meredith | Chief Commercial Officer | S - Sale | $30.44 | -7,522 | 64,507 | -10% | -$228,980 | ||||||
2026-03-27 | SLNO | Soleno Therapeutics Inc | Huang Michael F. | SVP of Clinical Development | S - Sale | $30.44 | -6,582 | 39,823 | -14% | -$200,365 | ||||||
| M | 2026-03-30 | ZBIO | Zenas Biopharma, Inc. | Moulder Leon O Jr | CEO | P - Purchase | $18.91 | +54,000 | 2,186,122 | +3% | +$1,021,140 | |||||
| D | 2026-03-31 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | S - Sale+OE | $32.12 | -21,338 | 9,597 | -69% | -$685,308 | |||||
| M | 2026-03-30 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale | $53.75 | -14,080 | 54,960 | -20% | -$756,834 | |||||
| D | 2026-03-06 | LGND | Ligand Pharmaceuticals Inc | Lamattina John L | Dir | S - Sale+OE | $200.76 | -2,161 | 30,724 | -7% | -$433,842 | |||||
2026-03-31 | ZBIO | Zenas Biopharma, Inc. | Lu Hongbo | Dir | P - Purchase | $20.00 | +75,000 | 422,968 | +22% | +$1,500,000 | ||||||
2026-03-30 | RZLT | Rezolute, Inc. | Evans Daron | CFO | P - Purchase | $2.85 | +10,000 | 511,462 | +2% | +$28,500 | ||||||
| M | 2026-03-27 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% | S - Sale | $4.89 | -100,997 | 431,094 | -19% | -$494,012 | |||||
| D | 2026-03-30 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $590.59 | -9,500 | 679,872 | -1% | -$5,610,564 | |||||
| D | 2026-03-30 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $593.17 | -10,000 | 18,876 | -35% | -$5,931,683 | |||||
| D | 2026-03-30 | UTHR | United Therapeutics Corp | Causey Christopher | Dir | S - Sale+OE | $604.64 | -1,300 | 4,190 | -24% | -$786,032 | |||||
| D | 2026-03-27 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $526.96 | -9,500 | 679,872 | -1% | -$5,006,100 | |||||
2026-03-30 | RAPP | Rapport Therapeutics, Inc. | Gault Cheryl | COO | S - Sale | $28.19 | -10,000 | 159,914 | -6% | -$281,857 | ||||||
2026-03-30 | ASMB | Assembly Biosciences, Inc. | Bjorkquist Jeanette M | PFO, PAO | S - Sale | $26.69 | -328 | 11,089 | -3% | -$8,755 | ||||||
2026-03-31 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale | $65.00 | -3,639 | 66,004 | -5% | -$236,535 | ||||||
2026-03-30 | ASMB | Assembly Biosciences, Inc. | White Nicole S | Chief Manufacturing Officer | S - Sale | $26.69 | -197 | 37,477 | -1% | -$5,258 | ||||||
| M | 2026-03-27 | MLYS | Mineralys Therapeutics, Inc. | Ra Capital Management, L.P. | Dir | P - Purchase | $23.75 | +369,000 | 7,692,750 | +5% | +$8,762,797 | |||||
| D | 2026-03-30 | INSM | Insmed Inc | Smith Michael Alexander | GC | S - Sale+OE | $150.98 | -19,638 | 51,871 | -27% | -$2,964,945 | |||||
2026-03-27 | VRTX | Vertex Pharmaceuticals Inc / Ma | Bozic Carmen | EVP, CMO | S - Sale | $450.95 | -2,329 | 33,076 | -7% | -$1,050,263 | ||||||
2026-03-30 | PGEN | Precigen, Inc. | Kirk Randal J | Dir, 10% | S - Sale | $3.30 | -4,772,781 | 116,301,090 | -4% | -$15,750,177 | ||||||
2026-03-27 | IMNM | Immunome Inc. | Siegall Clay B | Pres, CEO | P - Purchase | $19.67 | +25,450 | 690,704 | +4% | +$500,602 | ||||||
| M | 2026-03-25 | IBO | Impact Biomedical Inc. | Macko Todd D | CFO | S - Sale | $0.56 | -45,000 | 155,122 | -22% | -$25,330 | |||||
| D | 2026-03-26 | ROIV | Roivant Sciences Ltd. | Fitzgerald Meghan | Dir | S - Sale+OE | $27.45 | -70,000 | 42,963 | -62% | -$1,921,500 | |||||
| M | 2026-03-26 | WVE | Wave Life Sciences Ltd. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $6.23 | +8,772,496 | 27,004,320 | +48% | +$54,624,378 | |||||
| M | 2026-03-26 | LQDA | Liquidia Corp | Bloch Stephen M | Dir | S - Sale | $36.08 | -70,234 | 2,254,647 | -3% | -$2,533,766 | |||||
2026-03-26 | NGNE | Neurogene Inc. | Cvijic Christine Mikail | Pres, CFO | S - Sale | $21.62 | -2,558 | 103,240 | -2% | -$55,316 | ||||||
2026-03-26 | NGNE | Neurogene Inc. | McMinn Rachel | CEO | S - Sale | $22.07 | -3,352 | 1,344,307 | 0% | -$73,995 | ||||||
2026-03-26 | NGNE | Neurogene Inc. | Jordan Julie | Chief Medical Officer | S - Sale | $21.89 | -828 | 12,472 | -6% | -$18,128 | ||||||
2026-03-27 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | S - Sale | $30.98 | -16,358 | 9,597 | -63% | -$506,735 | ||||||
| D | 2026-03-26 | NUVL | Nuvalent, Inc. | Miller Deborah Ann | GC | S - Sale+OE | $98.73 | -5,500 | 59,634 | -8% | -$542,991 | |||||
2026-03-26 | CYPH | Cypherpunk Technologies Inc. | Mirabelli Christopher | Dir | S - Sale | $0.71 | -60,000 | 130,376 | -32% | -$42,630 | ||||||
2026-03-26 | XLO | Xilio Therapeutics, Inc. | Shannon James Samuel | Dir | P - Purchase | $8.79 | +5,000 | 10,000 | +100% | +$43,950 | ||||||
2026-03-27 | ANAB | Anaptysbio, Inc | Faga Daniel | Pres, CEO | S - Sale | $61.61 | -17,679 | 495,965 | -3% | -$1,089,199 | ||||||
| D | 2026-03-25 | TNGX | Tango Therapeutics, Inc. | Crystal Adam | Pres, R, D | S - Sale+OE | $20.11 | -12,000 | 112,622 | -10% | -$241,320 | |||||
| D | 2026-03-26 | PTGX | Protagonist Therapeutics, Inc | Molina Arturo Md | Chief Medical Officer | S - Sale+OE | $104.79 | -15,000 | 84,115 | -15% | -$1,571,850 | |||||
| D | 2026-03-26 | PTGX | Protagonist Therapeutics, Inc | Selick Harold E | Dir | S - Sale+OE | $105.00 | -24,000 | 60,845 | -28% | -$2,520,000 | |||||
| D | 2026-03-26 | PTGX | Protagonist Therapeutics, Inc | Ali Asif | CFO | S - Sale+OE | $104.24 | -24,765 | 60,753 | -29% | -$2,581,504 | |||||
| D | 2026-03-26 | CNTA | Centessa Pharmaceuticals Plc | Anderson Karen M. | Chief People Officer | S - Sale+OE | $30.12 | -41,076 | 62,085 | -40% | -$1,237,382 | |||||
| M | 2026-03-25 | KALV | Kalvista Pharmaceuticals, Inc. | Venrock Healthcare Capital Partners Iii, L.P. | 10% | S - Sale | $17.20 | -214,631 | 5,089,354 | -4% | -$3,691,148 | |||||
| D | 2026-03-25 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief Medical Officer | S - Sale+OE | $35.10 | -40,000 | 25,000 | -62% | -$1,404,024 | |||||
| D | 2026-03-25 | TYRA | Tyra Biosciences, Inc. | Kaplan Gilla | Dir | S - Sale+OE | $36.97 | -14,295 | 28,231 | -34% | -$528,506 | |||||
| D | 2026-03-26 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $535.81 | -9,500 | 679,872 | -1% | -$5,090,216 | |||||
| D | 2026-03-26 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $535.90 | -10,000 | 18,876 | -35% | -$5,359,005 | |||||
2026-03-25 | CORT | Corcept Therapeutics Inc | Belanoff Joseph K | CEO | S - Sale | $50.07 | -26,198 | 2,918,326 | -1% | -$1,311,826 | ||||||
2026-03-25 | LEGN | Legend Biotech Corp | Huang Ying | CEO | S - Sale | $8.77 | -9,936 | 247,438 | -4% | -$87,139 | ||||||
2026-03-26 | IBIO | Ibio, Inc. | Banjak Marc | GC | P - Purchase | $1.65 | +13,934 | 25,000 | +126% | +$23,055 | ||||||
| M | 2026-03-24 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale | $55.21 | -21,120 | 69,040 | -23% | -$1,166,105 | |||||
| D | 2026-03-26 | CNTA | Centessa Pharmaceuticals Plc | Weinhoff Gregory M | Chief Business Officer | S - Sale+OE | $30.00 | -23,998 | 65,925 | -27% | -$719,940 | |||||
| D | 2026-03-25 | ACAD | Acadia Pharmaceuticals Inc | Owen Adams Catherine | CEO | S - Sale+OE | $21.47 | -11,641 | 14,803 | -44% | -$249,932 | |||||
| D | 2026-03-25 | ACAD | Acadia Pharmaceuticals Inc | Rhodes Jennifer J | EVP, GC, SEC | S - Sale+OE | $21.47 | -3,844 | 11,280 | -25% | -$82,531 | |||||
| D | 2026-03-25 | ACAD | Acadia Pharmaceuticals Inc | Thompson Elizabeth H.Z. | EVP, Head of Research, Dev | S - Sale+OE | $21.47 | -3,435 | 3,280 | -51% | -$73,749 | |||||
| DM | 2026-03-25 | ACAD | Acadia Pharmaceuticals Inc | Kihara James | PRINCIPAL ACCOUNTING OFFICER | S - Sale+OE | $21.57 | -1,942 | 26,885 | -7% | -$41,895 | |||||
| DM | 2026-03-25 | ACAD | Acadia Pharmaceuticals Inc | Schneyer Mark C. | EVP, CFO | S - Sale+OE | $21.55 | -7,385 | 60,269 | -11% | -$159,136 | |||||
| D | 2026-03-25 | BCAX | Bicara Therapeutics Inc. | Raben David | Chief Medical Officer | S - Sale+OE | $18.95 | -5,500 | 55,286 | -9% | -$104,229 | |||||
| D | 2026-03-24 | DNTH | Dianthus Therapeutics, Inc. /De/ | Soteropoulos Paula | Dir | S - Sale+OE | $78.05 | -27,594 | 0 | -100% | -$2,153,712 | |||||
| M | 2026-03-24 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% | S - Sale | $5.56 | -17,909 | 532,091 | -3% | -$99,505 | |||||
| M | 2026-03-24 | GNLX | Genelux Corp | Smalling Ralph | Head of Regulatory | S - Sale | $2.46 | -585 | 68,073 | -1% | -$1,437 | |||||
2026-03-24 | GNLX | Genelux Corp | Cappello Joseph | Chief Technical Officer | S - Sale | $2.42 | -906 | 155,154 | -1% | -$2,193 | ||||||
2026-03-24 | GNLX | Genelux Corp | Yu Yong | SVP, Clinical Development | S - Sale | $2.42 | -906 | 144,938 | -1% | -$2,193 | ||||||
2026-03-24 | GNLX | Genelux Corp | Zindrick Thomas | Pres, CEO | S - Sale | $2.42 | -3,582 | 534,849 | -1% | -$8,668 | ||||||
2026-03-25 | RAPP | Rapport Therapeutics, Inc. | Yeleswaram Krishnaswamy | Chief Development Officer | S - Sale | $29.99 | -10,115 | 286,876 | -3% | -$303,355 | ||||||
| D | 2026-03-25 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $543.73 | -9,500 | 679,872 | -1% | -$5,165,475 | |||||
| D | 2026-03-26 | UTHR | United Therapeutics Corp | Thompson Tommy G | Dir | S - Sale+OE | $539.17 | -2,000 | 22,480 | -8% | -$1,078,332 | |||||
| DM | 2026-03-24 | NUVL | Nuvalent, Inc. | Balcom Alexandra | CFO | S - Sale+OE | $98.15 | -25,130 | 85,533 | -23% | -$2,466,610 | |||||
2026-03-23 | CYRX | Cryoport, Inc. | Stefanovich Robert | CFO | S - Sale | $8.18 | -1,094 | 279,277 | 0% | -$8,949 | ||||||
| D | 2026-03-23 | CYRX | Cryoport, Inc. | Shelton Jerrell | Pres, CEO | S - Sale+OE | $8.18 | -2,894 | 1,076,607 | 0% | -$23,673 | |||||
2026-03-23 | CYRX | Cryoport, Inc. | Sawicki Mark W | Chief Scientific Officer | S - Sale | $8.18 | -1,341 | 102,356 | -1% | -$10,969 | ||||||
2026-03-13 | TLPH | Talphera, Inc. | Angotti Vincent J. | CEO | P - Purchase | $0.59 | +213,310 | 800,705 | +36% | +$125,000 | ||||||
2026-03-23 | IBO | Impact Biomedical Inc. | Grady Jason | Dir | S - Sale | $0.65 | -50,000 | 250,182 | -17% | -$32,505 | ||||||
| DM | 2026-03-24 | PTGX | Protagonist Therapeutics, Inc | Patel Dinesh V Ph D | Pres, CEO | S - Sale+OE | $101.00 | -54,700 | 524,938 | -9% | -$5,524,700 | |||||
2026-03-24 | TPST | Tempest Therapeutics, Inc. | Angel Matthew | CEO, Pres, 10% | P - Purchase | $2.16 | +231,482 | 5,068,552 | +5% | +$500,001 | ||||||
2026-03-23 | RPRX | Royalty Pharma Plc | Coyne Terrance P. | EVP, CFO | S - Sale | $45.53 | -34,791 | 160,108 | -18% | -$1,583,989 | ||||||
| D | 2026-03-24 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $529.36 | -9,500 | 679,872 | -1% | -$5,028,919 | |||||
| D | 2026-03-23 | LQDA | Liquidia Corp | Moomaw Scott | Chief Commercial Officer | S - Sale+OE | $36.79 | -18,314 | 187,640 | -9% | -$673,752 | |||||
| M | 2025-04-14 | PYXS | Pyxis Oncology, Inc. | Humphrey Rachel | Dir | S - Sale | $1.03 | -15,496 | 81,309 | -16% | -$15,917 | |||||
2026-03-23 | LGND | Ligand Pharmaceuticals Inc | Sabba Stephen L | Dir | S - Sale | $207.87 | -1,000 | 32,793 | -3% | -$207,873 | ||||||
| D | 2026-03-20 | RNXT | Renovorx, Inc. | Marton Laurence | Dir | P - Purchase | $0.00 | +9,720 | 9,720 | New | +$0 | |||||
| D | 2026-03-20 | RNXT | Renovorx, Inc. | Bagai Shaun | CEO | P - Purchase | $0.00 | +24,300 | 364,340 | +7% | +$0 | |||||
| D | 2026-03-20 | RNXT | Renovorx, Inc. | Voll Mark | CFO | P - Purchase | $0.00 | +97,200 | 97,200 | New | +$0 | |||||
| D | 2026-03-23 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | S - Sale+OE | $18.52 | -9,200 | 145,355 | -6% | -$170,348 | |||||
| D | 2026-03-23 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $2.86 | -6,500 | 0 | -100% | -$18,568 | |||||
2026-03-23 | OKUR | Onkure Therapeutics, Inc. | Saccomano Nicholas A | Pres, CEO | S - Sale | $4.16 | -86 | 7,333 | -1% | -$357 | ||||||
2026-03-23 | OKUR | Onkure Therapeutics, Inc. | Leverone Jason A. | CFO | S - Sale | $4.16 | -301 | 16,000 | -2% | -$1,251 | ||||||
2026-03-23 | VTRS | Viatris Inc | Campbell Paul | See Remarks | S - Sale | $13.28 | -21,350 | 366,606 | -6% | -$283,539 | ||||||
| D | 2026-03-20 | ATAI | Ataibeckley Inc. | Craig Kevin James | Chief Medical Officer | S - Sale+OE | $3.55 | -100,000 | 8,437 | -92% | -$355,000 | |||||
| D | 2026-03-20 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale+OE | $36.01 | -11,767 | 2,231 | -84% | -$423,730 | |||||
| D | 2026-03-23 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $527.48 | -10,000 | 18,876 | -35% | -$5,274,802 | |||||
| D | 2026-03-23 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $527.01 | -9,500 | 679,872 | -1% | -$5,006,558 | |||||
2026-03-23 | UTHR | United Therapeutics Corp | Olian Judy D. | Dir | S - Sale | $530.00 | -200 | 4,245 | -4% | -$106,000 | ||||||
2026-03-20 | STOK | Stoke Therapeutics, Inc. | Allan Jonathan | GC, Corp Sec | S - Sale | $33.69 | -9,293 | 19,543 | -32% | -$313,038 | ||||||
2026-03-24 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $72.00 | +39,665 | 500,000 | +9% | +$2,855,880 | ||||||
| M | 2026-03-20 | IMNM | Immunome Inc. | Wagenheim Philip | Dir | S - Sale | $20.55 | -65,000 | 341,147 | -16% | -$1,335,626 | |||||
2026-03-19 | IONS | Ionis Pharmaceuticals Inc | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | S - Sale | $70.97 | -5,812 | 63,890 | -8% | -$412,486 | ||||||
| D | 2026-03-20 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $524.99 | -9,500 | 679,872 | -1% | -$4,987,387 | |||||
2026-03-19 | ALXO | Alx Oncology Holdings Inc | Lettmann Jason | CEO | S - Sale | $2.17 | -12,311 | 293,609 | -4% | -$26,715 | ||||||
2026-03-19 | ALXO | Alx Oncology Holdings Inc | Pinto Shelly | SVP, Finance, CAO | S - Sale | $2.17 | -903 | 86,805 | -1% | -$1,960 | ||||||
2026-03-19 | IBIO | Ibio, Inc. | Duran Felipe | CFO | P - Purchase | $2.02 | +24,835 | 35,974 | +223% | +$50,132 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |